Prelude Therapeutics Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; it does not provide a standalone Q4 income statement. Prelude is a clinical-stage oncology company with no approved products or product revenue.
Financial and operating performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $103.4 million | $92.9 million |
| General and administrative expense | $28.9 million | $30.7 million |
| Total operating expenses | $132.3 million | $123.5 million |
| Net loss | $121.8 million | $115.4 million |
| Net loss per share, basic and diluted | $2.02 | $2.44 |
| Net cash used in operating activities | $107.1 million | $83.7 million |
| Cash, cash equivalents and marketable securities at year-end | $232.9 million | $201.7 million |
Operating margin and conventional profitability margins are not meaningful because the company generated no revenue. Other income, net was $10.4 million, primarily interest income and Delaware research and development tax credits. Accumulated deficit was $456.4 million.
At year-end, total assets were $277.7 million, total liabilities $40.6 million, and stockholders’ equity $237.1 million. The filing reports no credit facility or committed debt financing. Cash and marketable securities include $207.6 million of marketable securities and $25.3 million of cash and cash equivalents; an additional $4.0 million was restricted cash.
Material changes versus FY2022
- Net loss increased $6.4 million, or about 5.5%; R&D expense rose $10.5 million, while G&A expense fell $1.8 million.
- Operating cash use increased $23.3 million. The company attributed cash use primarily to product-candidate development.
- Financing activities provided $136.4 million, mainly from common stock and pre-funded warrant offerings, versus $0.8 million in FY2022. Net proceeds from the 2023 offerings were approximately $135.7 million.
- R&D spending shifted among programs: PRT3789 and PRT3645 incurred $9.7 million and $4.8 million, respectively, in FY2023; PRMT5 program costs were reported as a net credit of $0.2 million versus $13.3 million of expense in FY2022.
Pipeline, outlook and key risks
- PRT3789 (SMARCA2 degrader): Phase 1; the company reported dose-dependent target degradation and an acceptable safety profile to date. It expected to complete monotherapy dose escalation around mid-2024 and present initial data in the second half of 2024.
- PRT2527 (CDK9 inhibitor): Completed a Phase 1 dose-escalation study in solid tumors; 12 mg/m² once weekly was selected as the optimal dose in that study. Development is proceeding in hematologic cancers, including B-cell malignancies and AML, with a zanubrutinib combination initiated. Management expected B-cell monotherapy escalation completion around mid-2024.
- PRT3645 (CDK4/6 inhibitor): Phase 1 dose escalation ongoing. Management planned to complete escalation in 2024 and explore further development with external partners.
- PRT7732: Oral SMARCA2 degrader in IND-enabling studies; management expected Phase 1 entry in the second half of 2024.
- Portfolio changes and collaboration: Prelude discontinued PRT1419 development, prioritizing PRT2527. Its AbCellera collaboration covers up to five precision ADC programs; collaboration costs were not material in FY2023.
- Funding outlook: Management expected existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into 2026. This estimate depends on assumptions and the company expects to need additional capital to fund longer-term plans.
- Principal risks: No product revenue, continuing losses, early-stage clinical programs and uncertain trial outcomes; dependence on additional financing; patient-enrollment and regulatory risks; reliance on third-party manufacturers without redundant supply arrangements; competition; and potential dilution from future financing. Clinical milestones and timing are forward-looking expectations, not guarantees.
- Other commitments: The new Wilmington office and laboratory lease has an initial 162-month term. Estimated total payments are $43.2 million through May 2037; the 2024 lease payment obligation is approximately $1.6 million. Management reported no material pending legal proceedings.
Important facts for investors to verify
- Whether 2024 clinical milestones were achieved, and the complete safety, efficacy and dose data for PRT3789, PRT2527 and PRT3645.
- Cash burn, investment balances and the assumptions supporting the stated runway into 2026; confirm the timing and terms of any subsequent financing.
- The potential dilution from 2023 equity offerings and pre-funded warrants, and the voting and conversion provisions for the company’s dual-class common stock.
- The financial and development terms of the AbCellera collaboration, including cost-sharing, opt-out and commercial rights.
- Manufacturing capacity and supply continuity, since Prelude relies on third parties and reports no redundant supply arrangements for key materials.
The independent auditor issued an unqualified opinion on the FY2023 and FY2022 financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an opinion on internal control effectiveness.